516 related articles for article (PubMed ID: 22451584)
21. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
22. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
Yun S; Anwer F; Vincelette ND
BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24810451
[No Abstract] [Full Text] [Related]
23. Reversible pre-capillary pulmonary hypertension due to dasatinib.
Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
25. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
26. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Taylor MJ; Scuffham PA
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
[TBL] [Abstract][Full Text] [Related]
27. Chronic myeloid leukemia: advances in diagnosis and management.
Noronha S; Sawyer S
JAAPA; 2013 Feb; 26(2):26-9. PubMed ID: 23409382
[No Abstract] [Full Text] [Related]
28. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Breccia M; Alimena G
Expert Opin Drug Saf; 2010 Sep; 9(5):713-21. PubMed ID: 20722490
[TBL] [Abstract][Full Text] [Related]
29. Leukemia. Q&A highlights.
Frame D; Sessions J; Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S22. PubMed ID: 18056929
[No Abstract] [Full Text] [Related]
30. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
31. Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.
Harbaum L; Marx A; Goekkurt E; Schafhausen P; Atanackovic D
Int J Hematol; 2014 Jan; 99(1):91-4. PubMed ID: 24264834
[TBL] [Abstract][Full Text] [Related]
32. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Jabbour E; Kantarjian HM; Saglio G; Steegmann JL; Shah NP; Boqué C; Chuah C; Pavlovsky C; Mayer J; Cortes J; Baccarani M; Kim DW; Bradley-Garelik MB; Mohamed H; Wildgust M; Hochhaus A
Blood; 2014 Jan; 123(4):494-500. PubMed ID: 24311723
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
[TBL] [Abstract][Full Text] [Related]
34. [Adherence and toxicity to tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
González Rosa V; Gutiérrez Nicolás F; Gavira Moreno R; Viña Romero MM; Moreno Carvajal MT; Gázquez Pérez R
Farm Hosp; 2013; 37(6):434-40. PubMed ID: 24256006
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
[TBL] [Abstract][Full Text] [Related]
36. Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.
Ritchie DS; McBean M; Westerman DA; Kovalenko S; Seymour JF; Dobrovic A
Blood; 2008 Mar; 111(5):2896-8. PubMed ID: 18073350
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
[TBL] [Abstract][Full Text] [Related]
38. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Breccia M
Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
[No Abstract] [Full Text] [Related]
39. [Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
Miura M; Takahashi N
Rinsho Ketsueki; 2013 Oct; 54(10):1720-9. PubMed ID: 24064822
[No Abstract] [Full Text] [Related]
40. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; Cervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP
Blood; 2007 Mar; 109(6):2303-9. PubMed ID: 17138817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]